• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于排除风险预测模型和附加预测因子的 AUC 的简单决策分析函数。

Simple Decision-Analytic Functions of the AUC for Ruling Out a Risk Prediction Model and an Added Predictor.

机构信息

Division of Cancer Prevention, National Cancer Institute, Bethesda, USA (SGB).

出版信息

Med Decis Making. 2018 Feb;38(2):225-234. doi: 10.1177/0272989X17732994. Epub 2017 Oct 12.

DOI:10.1177/0272989X17732994
PMID:29025299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5920780/
Abstract

BACKGROUND

When using risk prediction models, an important consideration is weighing performance against the cost (monetary and harms) of ascertaining predictors.

METHODS

The minimum test tradeoff (MTT) for ruling out a model is the minimum number of all-predictor ascertainments per correct prediction to yield a positive overall expected utility. The MTT for ruling out an added predictor is the minimum number of added-predictor ascertainments per correct prediction to yield a positive overall expected utility.

RESULTS

An approximation to the MTT for ruling out a model is 1/[P (H(AUC)], where H(AUC) = AUC - {½ (1-AUC)}, AUC is the area under the receiver operating characteristic (ROC) curve, and P is the probability of the predicted event in the target population. An approximation to the MTT for ruling out an added predictor is 1 /[P {(H(AUC) - H(AUC )], where Model 2 includes an added predictor relative to Model 1.

LIMITATION

The latter approximation requires the Tangent Condition that the true positive rate at the point on the ROC curve with a slope of 1 is larger for Model 2 than Model 1.

CONCLUSION

These approximations are suitable for back-of-the-envelope calculations. For example, in a study predicting the risk of invasive breast cancer, Model 2 adds to the predictors in Model 1 a set of 7 single nucleotide polymorphisms (SNPs). Based on the AUCs and the Tangent Condition, an MTT of 7200 was computed, which indicates that 7200 sets of SNPs are needed for every correct prediction of breast cancer to yield a positive overall expected utility. If ascertaining the SNPs costs $500, this MTT suggests that SNP ascertainment is not likely worthwhile for this risk prediction.

摘要

背景

在使用风险预测模型时,需要权衡模型性能与确定预测因素的成本(货币和危害)。

方法

排除模型的最小测试权衡(MTT)是指每正确预测一次所需的所有预测因素的最小确定数,以产生正的总体预期效用。排除附加预测因素的 MTT 是指每正确预测一次所需的附加预测因素的最小确定数,以产生正的总体预期效用。

结果

排除模型的 MTT 的近似值为 1/[P(H(AUC)],其中 H(AUC)= AUC - {½(1-AUC)},AUC 是接收者操作特征(ROC)曲线下的面积,P 是目标人群中预测事件的概率。排除附加预测因素的 MTT 的近似值为 1 /[P {(H(AUC)-H(AUC )],其中模型 2相对于模型 1包含一个附加预测因素。

局限性

后一种近似值需要切线条件,即模型 2的 ROC 曲线上斜率为 1 的点的真阳性率大于模型 1。

结论

这些近似值适用于粗略计算。例如,在一项预测浸润性乳腺癌风险的研究中,模型 2在模型 1的预测因素中增加了一组 7 个单核苷酸多态性(SNP)。基于 AUC 和切线条件,计算出的 MTT 为 7200,这表明每正确预测一次乳腺癌,需要进行 7200 次 SNP 检测才能产生正的总体预期效用。如果 SNP 检测的成本为 500 美元,则 MTT 表明 SNP 检测对于这种风险预测可能不值得。

相似文献

1
Simple Decision-Analytic Functions of the AUC for Ruling Out a Risk Prediction Model and an Added Predictor.用于排除风险预测模型和附加预测因子的 AUC 的简单决策分析函数。
Med Decis Making. 2018 Feb;38(2):225-234. doi: 10.1177/0272989X17732994. Epub 2017 Oct 12.
2
Evaluating Risk Prediction with Data Collection Costs: Novel Estimation of Test Tradeoff Curves.评估数据收集成本下的风险预测:测试权衡曲线的新估计方法。
Med Decis Making. 2024 Jan;44(1):53-63. doi: 10.1177/0272989X231208673. Epub 2023 Nov 22.
3
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
4
How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through.如何解释 AUC 随着额外风险预测标志物的增加而略有增加:决策分析派上用场。
Stat Med. 2014 Sep 28;33(22):3946-59. doi: 10.1002/sim.6195. Epub 2014 May 13.
5
Metrics for Evaluating Polygenic Risk Scores.评估多基因风险评分的指标。
JNCI Cancer Spectr. 2020 Dec 23;5(1). doi: 10.1093/jncics/pkaa106. eCollection 2021 Feb.
6
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
7
Small improvement in the area under the receiver operating characteristic curve indicated small changes in predicted risks.受试者工作特征曲线下面积的小幅改善表明预测风险的微小变化。
J Clin Epidemiol. 2016 Nov;79:159-164. doi: 10.1016/j.jclinepi.2016.07.002. Epub 2016 Jul 16.
8
Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.评估 Canary 前列腺主动监测研究中 4Kscore 的四个 Kallikrein 面板对预测男性高级别前列腺癌的价值。
Eur Urol. 2017 Sep;72(3):448-454. doi: 10.1016/j.eururo.2016.11.017. Epub 2016 Nov 23.
9
Decision Curve Analysis of In-Hospital Mortality Prediction Models: The Relative Value of Pre- and Intraoperative Data For Decision-Making.住院患者死亡率预测模型的决策曲线分析:术前和术中数据在决策中的相对价值。
Anesth Analg. 2024 Sep 1;139(3):617-28. doi: 10.1213/ANE.0000000000006874. Epub 2024 Feb 5.
10
Decision curve analysis confirms higher clinical utility of multi-domain versus single-domain prediction models in patients with open abdomen treatment for peritonitis.决策曲线分析证实,在接受开放性腹部治疗的腹膜炎患者中,多领域预测模型比单领域预测模型具有更高的临床实用性。
BMC Med Inform Decis Mak. 2023 Apr 6;23(1):63. doi: 10.1186/s12911-023-02156-w.

引用本文的文献

1
Evaluating Risk Prediction with Data Collection Costs: Novel Estimation of Test Tradeoff Curves.评估数据收集成本下的风险预测:测试权衡曲线的新估计方法。
Med Decis Making. 2024 Jan;44(1):53-63. doi: 10.1177/0272989X231208673. Epub 2023 Nov 22.
2
From high school to postsecondary education, training, and employment: Predicting outcomes for young adults with autism spectrum disorder.从高中到高等教育、培训及就业:预测自闭症谱系障碍青年成人的发展结果。
Autism Dev Lang Impair. 2022 Apr 18;7:23969415221095019. doi: 10.1177/23969415221095019. eCollection 2022 Jan-Dec.
3
Metrics for Evaluating Polygenic Risk Scores.

本文引用的文献

1
The summary test tradeoff: a new measure of the value of an additional risk prediction marker.总结性检验权衡:一种衡量额外风险预测标志物价值的新方法。
Stat Med. 2017 Dec 10;36(28):4491-4494. doi: 10.1002/sim.7132.
2
Net reclassification index at event rate: properties and relationships.事件发生率下的净重新分类指数:特性与关系
Stat Med. 2017 Dec 10;36(28):4455-4467. doi: 10.1002/sim.7041. Epub 2016 Jul 18.
3
Net reclassification indices for evaluating risk prediction instruments: a critical review.用于评估风险预测工具的净重新分类指数:批判性评价。
评估多基因风险评分的指标。
JNCI Cancer Spectr. 2020 Dec 23;5(1). doi: 10.1093/jncics/pkaa106. eCollection 2021 Feb.
4
Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening.评估4种生物标志物的简单方法:替代终点、预后、预测和癌症筛查。
Biomark Insights. 2020 Aug 4;15:1177271920946715. doi: 10.1177/1177271920946715. eCollection 2020.
Epidemiology. 2014 Jan;25(1):114-21. doi: 10.1097/EDE.0000000000000018.
4
Evaluating a new marker for risk prediction using the test tradeoff: an update.使用检验权衡评估一种用于风险预测的新标志物:最新进展
Int J Biostat. 2012 Mar 22;8(1):/j/ijb.2012.8.issue-1/1557-4679.1395/1557-4679.1395.xml. doi: 10.1515/1557-4679.1395.
5
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information.评估结合遗传和临床信息的乳腺癌风险模型的临床有效性。
J Natl Cancer Inst. 2010 Nov 3;102(21):1618-27. doi: 10.1093/jnci/djq388. Epub 2010 Oct 18.
6
Using relative utility curves to evaluate risk prediction.使用相对效用曲线评估风险预测。
J R Stat Soc Ser A Stat Soc. 2009 Oct 1;172(4):729-748. doi: 10.1111/j.1467-985X.2009.00592.x.
7
Assessment of claims of improved prediction beyond the Framingham risk score.对超越弗雷明汉姆风险评分的预测改善声明的评估。
JAMA. 2009 Dec 2;302(21):2345-52. doi: 10.1001/jama.2009.1757.
8
Putting risk prediction in perspective: relative utility curves.正确看待风险预测:相对效用曲线。
J Natl Cancer Inst. 2009 Nov 18;101(22):1538-42. doi: 10.1093/jnci/djp353. Epub 2009 Oct 20.
9
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.国家外科辅助乳腺和肠道项目(NSABP)他莫昔芬与雷洛昔芬(STAR)试验
Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51.
10
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.评估新标志物的附加预测能力:从ROC曲线下面积到重新分类及其他。
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12. doi: 10.1002/sim.2929.